At 4 years, treatment of NPDR with aflibercept vs sham treatment resulted in statistically significant anatomic improvement, but no improvement in visual acuity (JAMA)
Diabetes News
Tag: aflibercept
Clinical efficacy of intravitreal aflibercept versus panretinal photocoagulation for best corrected visual acuity in patients with proliferative diabetic retinopathy at 52 weeks
Patients with proliferative diabetic retinopathy who were treated with intravitreal aflibercept had an improved outcome at 1 year compared with those treated with PRP standard care (Lancet)
Cost-effectiveness of ranibizumab versus aflibercept in the treatment of visual impairment due to diabetic macular edema: a UK healthcare perspective
From a UK healthcare perspective, ranibizumab provides greater health gains with lower overall costs than aflibercept in patients with VI due to DME (ClinicoEconomics and Outcomes Research)
Aflibercept, Bevacizumab, or Ranibizumab for Diabetic Macular Edema
Intravitreous aflibercept, bevacizumab, or ranibizumab improved vision in eyes with center-involved diabetic macular edema, but the relative effect depended on baseline visual acuity. When the initial visual-acuity loss was mild, there were no apparent differences, on average, among study groups. At worse levels of initial visual acuity, aflibercept was more effective at improving vision (NEJM)
FDA approves new treatment for diabetic retinopathy in patients with diabetic macular edema
The U.S. Food and Drug Administration expand the approved use for Eylea (aflibercept) injection to treat diabetic retinopathy in patients with diabetic macular edema
Glycosmedia is also available as an App: